Christopher Inhulsen, MD
Internal Medicine · Cartersville, GANPI 1124324967
Payments from drug & device makers
Across 314 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$907
- AbbVie$627
- Pfizer$549
- Lilly USA, LLC$493
- Amgen$344
- AstraZeneca$267
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,273100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $907 |
| AbbVie(2 entities) | 35 | $627 |
| Pfizer | 37 | $549 |
| Lilly USA, LLC | 34 | $493 |
| Amgen | 20 | $344 |
| AstraZeneca | 20 | $267 |
| GSK | 16 | $266 |
| Sanofi-aventis U.S. LLC | 11 | $192 |
| Dexcom, Inc. | 6 | $192 |
| Boehringer Ingelheim | 10 | $168 |
| Astellas Pharma US Inc | 8 | $141 |
| Johnson & Johnson | 13 | $139 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Sumitomo Pharma America, Inc. | 7 | $105 |
| Novartis | 5 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $96 |
| Abbott | 5 | $91 |
| Idorsia Pharmaceuticals US Inc | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 3 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Merck | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $20 |
| Medtronic | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
How this compares
$5,293 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 164 | $164,843 |
| OzempicSemaglutide | 112 | $125,793 |
| EliquisApixaban | 94 | $91,696 |
| MounjaroTirzepatide | 60 | $75,941 |
| FarxigaDapagliflozin Propanediol | 47 | $52,637 |
| TrulicityDulaglutide | 36 | $48,304 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $44,505 |
| RybelsusSemaglutide | 37 | $42,948 |
| LinzessLinaclotide | 34 | $41,750 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $34,211 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $31,551 |
| XareltoRivaroxaban | 24 | $31,546 |
| ProliaDenosumab | 16 | $27,044 |
| JanuviaSitagliptin Phosphate | 23 | $27,019 |
| MyrbetriqMirabegron | 26 | $21,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $168 | $181,973188 claims |
| Novo NordiskOzempic, Rybelsus | $907 | $168,740149 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin N | $493 | $126,914109 claims |
| PfizerEliquis | $549 | $91,69694 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $267 | $67,53561 claims |
| AbbVieLinzess, Vraylar, Synthroid | $627 | $60,26574 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $266 | $59,32558 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $192 | $34,21127 claims |
| Johnson & JohnsonXarelto | $139 | $31,54624 claims |
| AmgenProlia | $344 | $27,04416 claims |
| MerckJanuvia | $30 | $27,01923 claims |
| Astellas Pharma US IncMyrbetriq | $141 | $21,19726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Cartersville
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.